Rapidly Characterize Antibody-Drug Conjugates and Derive Drug-to-Antibody Ratios Using LC/MS
Available on demand
Antibody Drug Conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs. ADCs are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers. Characterization of ADCs is challenging due to their complex and heterogeneous nature. One of the quality attributes of ADCs is drug-to-antibody ratio (DAR). In this presentation, we will present multiple, complementary approaches to characterizing the ADC DAR values using LC/MS.
In this webinar, Dr. Ning Tang, Biopharma Discovery Segment Marketing Manager at Agilent Technologies, will discuss:
- An overview of the major challenges in ADC characterization
- How LC/MS can be used to enable an in-depth ADC characterization profile
- Innovative technologies being used for rapid DAR calculations
- How you can increase the confidence in your discovery or development of ADC biotherapeutics
For Research Use Only. Not for use in diagnostic procedures.
Agilent Technologies